Journal article
Which azithromycin regimen should be used for treating Mycoplasma genitalium A meta-analysis
P Horner, SM Ingle, F Garrett, K Blee, F Kong, P Muir, H Moi
Sexually Transmitted Infections | BMJ PUBLISHING GROUP | Published : 2018
Abstract
Background There is increasing evidence that azithromycin 1 g is driving the emergence of macrolide resistance in Mycoplasma genitalium worldwide. We undertook a meta-analysis of M. genitalium treatment studies using azithromycin 1 g single dose and azithromycin 500 mg on day 1 then 250 mg daily for 4 days (5-day regimen) to determine rates of treatment failure and resistance in both regimens. Methods The online databases PubMed and Medline were searched using terms "Mycoplasma genitalium", "macrolide"or "azithromycin"and "resistance"up to April 2016. Studies were eligible if they: used azithromycin 1 g or 5 days, assessed patients for macrolide resistant genetic mutations prior to treatment..
View full abstractRelated Projects (3)
Grants
Funding Acknowledgements
This work was supported by the National Institute of Health Research Health Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at the University of Bristol in partnership with Public Health England (PHE).